tiletamine hydrochloride has been researched along with Complication, Postoperative in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asahi, Y; Emoto, S; Kamachi, H; Koshizuka, Y; Kuraya, D; Matsushita, M; Ogura, M; Ono, H; Ozaki, M; Shibasaki, S; Todo, S; Umezawa, K; Watanabe, M; Yamashita, K; Yoshida, T | 1 |
| Asahi, Y; Harashima, H; Kamachi, H; Koshizuka, Y; Kuraya, D; Matsushita, M; Nakamura, T; Ogura, M; Ozaki, M; Todo, S; Umezawa, K; Watanabe, M; Yamashita, K; Yoshida, T | 1 |
2 other study(ies) available for tiletamine hydrochloride and Complication, Postoperative
| Article | Year |
|---|---|
Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance.
Topics: Animals; Benzamides; Cyclohexanones; Cytokines; Dendritic Cells; Graft Survival; HMGB1 Protein; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; NF-kappa B; Postoperative Complications; Tacrolimus; Transplantation, Homologous | 2013 |
Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage.
Topics: Animals; Benzamides; Cyclohexanones; Diabetes Mellitus, Experimental; HMGB1 Protein; Islets of Langerhans Transplantation; Liposomes; Macrophage Activation; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Postoperative Complications; Streptozocin | 2013 |